You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
A股異動 | 甘李藥業(603087.SH)漲停 子公司獲得美國FDA藥品臨牀試驗批准
格隆匯 07-08 10:23
格隆匯7月8日丨甘李藥業(603087.SH)漲停,封單近9萬手,現報177.69元,暫成交1569萬元,最新總市值712億元。甘李藥業昨晚公佈,近日,公司全資子公司甘李藥業美國公司獲得美國食品藥品監督管理局(簡稱“FDA”)同意GLR2007進行I期臨牀試驗的批准。子公司將在美國開展該項I期臨牀試驗。該藥品為公司自主研發的創新型小分子化學藥物,擬用於包括腦膠質瘤在內的多種晚期實體腫瘤治療。值得一提的是,甘李藥業於6月29日登陸上交所,上市後至今8個交易日較發行價63.32元已累漲1.8倍。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account